Cellectar Biosciences (NASDAQ: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer-targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. The company’s lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a pre-clinical stage product candidate, with plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information, visit the company’s website at www.cellectarbiosciences.com